AptaBio Therapeutics Inc.
293780.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$175.3B
Close$
$-7637.65
231.9% downside
Current Fair Value
231.9% downsideOvervalued by 231.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $175.30 Billion |
|---|---|
| Enterprise Value | $165.50 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-607.49 |
| Beta | 0.98 |
| Outstanding Shares | 28,093,405 |
Return
| Return on Equity | -35.23% |
|---|---|
| Return on Assets | -27.34% |
| Return on Invested Capital | -51.20% |
Valuation & Multiples
| P/E Ratio | -11.27 |
|---|---|
| PEG | 8.91 |
| Price to Sales | 34.26 |
| Price to Book Ratio | 3.85 |
| Enterprise Value to Revenue | 34.82 |
| Enterprise Value to EBIT | -7.1 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About AptaBio Therapeutics Inc.
45 employees
CEO: Jin Lee Soo AptaBio Therapeutics Inc. specializes in the discovery and advancement of innovative therapeutic agents. Its core activities encompass developing specific inhibitors for the NOX enzyme family and crafting aptamer-based anti-cancer medici...